Endo, Impax face class-action over antitrust claims

Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Endo pays $2.3m to settle states antitrust claims

22 July 2019 Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.

Americas

Endo resolves FTC allegations over Lidoderm and Opana ER

24 January 2017 Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

Americas

Generic maker pays $145m to settle antitrust suit

21 July 2022 California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.

More on this story

Americas

Endo pays $2.3m to settle states antitrust claims

Americas

Endo resolves FTC allegations over Lidoderm and Opana ER

24 January 2017 Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

Americas

Generic maker pays $145m to settle antitrust suit

21 July 2022 California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.

More on this story

Americas

Endo pays $2.3m to settle states antitrust claims

Americas

Endo resolves FTC allegations over Lidoderm and Opana ER

24 January 2017 Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

Americas

Generic maker pays $145m to settle antitrust suit

21 July 2022 California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.